BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2024-04-11 14:00 |
BioSenic - Press Release (EN) - plan de restructuration - final(1300533.1).PDF
|
English | PDF • 275.6 KB | ||
| 2024-04-11 14:00 |
BioSenic - Press Release (FR) - plan de restructuration - final(1300534.1).PDF
|
French | PDF • 269.1 KB | ||
| 2024-03-29 07:00 |
BIOS_PR_2024-March_Denominator_EN_final(1294294.2).pdf
|
English | PDF • 224.0 KB | ||
| 2024-03-29 07:00 |
BIOS_PR_2024-mars_Denominator_FR_final(1294295.2).pdf
|
French | PDF • 259.3 KB | ||
| 2024-03-12 07:00 |
BIOS_PR_ 024 03 06_Article_2cyclesATO_cGvHD_EN_Final.pdf
|
English | PDF • 287.0 KB | ||
| 2024-03-12 07:00 |
BIOS_PR_2024 03 06_Article_2cyclesATO_cGvHD_FR_FINAL.pdf
|
French | PDF • 273.0 KB | ||
| 2024-02-29 07:00 |
BIOS_PR_2024-February_Denominator_EN_Final.pdf
|
English | PDF • 275.3 KB | ||
| 2024-02-29 07:00 |
BIOS_PR_2024-février_Denominator_FR_Final.pdf
|
French | PDF • 196.0 KB | ||
| 2024-01-30 07:00 |
BIOS_PR_2024-01-30_ATO-Cu_Patent_Ca_EN_FINAL.pdf
|
English | PDF • 294.3 KB | ||
| 2024-01-30 07:00 |
BIOS_PR_2024-01-30_ATO-Cu_Patent_Ca_FR_FINAL.pdf
|
French | PDF • 286.6 KB | ||
| 2024-01-15 07:00 |
BIOS_PR _Phebra licensing and MDA on cGvHD _EN_Final.pdf
|
English | PDF • 264.3 KB | ||
| 2024-01-15 07:00 |
BIOS_PR _Phebra licensing and MDA on cGvHD _FR_Final.pdf
|
French | PDF • 245.6 KB | ||
| 2024-01-15 07:00 |
BIOS_PR_2024-01-15_Transparency Notification_Multiple_EN_Final.pdf
|
English | PDF • 250.7 KB | ||
| 2024-01-15 07:00 |
BIOS_PR_2023-10-16_Transparency Notification_Multiple_FR_Final.pdf
|
French | PDF • 253.1 KB | ||
| 2024-01-08 18:00 |
BIOS_PR_2024_ABO_EN_Final.pdf
|
English | PDF • 245.7 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
